BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012;217:235-43. [PMID: 21852019 DOI: 10.1016/j.imbio.2011.07.022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Szilágyi A, Kiss N, Bereczki C, Tálosi G, Rácz K, Túri S, Györke Z, Simon E, Horváth E, Kelen K, Reusz GS, Szabó AJ, Tulassay T, Prohászka Z. The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2013;28:2237-45. [PMID: 23787556 DOI: 10.1093/ndt/gft198] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
2 Chidambaram AC, Krishnamurthy S, Deepthi B, Karunakar P, Maulik K, Peela SCM, Sistla S, Jinkala SR. Severe acute kidney injury in a 3-year-old boy with fever and pleural effusion: Answers. Pediatr Nephrol 2020;35:2279-83. [PMID: 32468115 DOI: 10.1007/s00467-020-04591-7] [Reference Citation Analysis]
3 Keir LS, Saleem MA. Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2014;29:1895-902. [PMID: 23843163 DOI: 10.1007/s00467-013-2561-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
4 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
5 Agarwal HS, Latifi SQ. Streptococcus Pneumoniae-Associated Hemolytic Uremic Syndrome in the Era of Pneumococcal Vaccine. Pathogens 2021;10:727. [PMID: 34207609 DOI: 10.3390/pathogens10060727] [Reference Citation Analysis]
6 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
7 Watson CN, Kerrigan SW, Cox D, Henderson IR, Watson SP, Arman M. Human platelet activation by Escherichia coli: roles for FcγRIIA and integrin αIIbβ3. Platelets 2016;27:535-40. [PMID: 27025455 DOI: 10.3109/09537104.2016.1148129] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
8 Petruzziello-Pellegrini TN, Moslemi-Naeini M, Marsden PA. New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome. Virulence 2013;4:556-63. [PMID: 23955166 DOI: 10.4161/viru.26143] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
9 Keir LS, Langman CB. Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis. Transfus Apher Sci 2016;54:203-11. [PMID: 27156109 DOI: 10.1016/j.transci.2016.04.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
10 Ehrlenbach S, Rosales A, Posch W, Wilflingseder D, Hermann M, Brockmeyer J, Karch H, Satchell SC, Würzner R, Orth-Höller D. Shiga toxin 2 reduces complement inhibitor CD59 expression on human renal tubular epithelial and glomerular endothelial cells. Infect Immun 2013;81:2678-85. [PMID: 23690395 DOI: 10.1128/IAI.01079-12] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
11 New HV, Berryman J, Bolton-maggs PHB, Cantwell C, Chalmers EA, Davies T, Gottstein R, Kelleher A, Kumar S, Morley SL, Stanworth SJ; the British Committee for Standards in Haematology. Guidelines on transfusion for fetuses, neonates and older children. Br J Haematol 2016;175:784-828. [DOI: 10.1111/bjh.14233] [Cited by in Crossref: 122] [Cited by in F6Publishing: 95] [Article Influence: 20.3] [Reference Citation Analysis]
12 Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13:300-317. [PMID: 29042465 DOI: 10.2215/cjn.00620117] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 20.6] [Reference Citation Analysis]
13 Gilbert RD, Nagra A, Haq MR. Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae? Med Hypotheses 2013;81:400-3. [PMID: 23786906 DOI: 10.1016/j.mehy.2013.05.030] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
14 Bitzan M, AlKandari O, Whittemore B, Yin XL. Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept. Int J Med Microbiol 2018;308:1096-104. [PMID: 30177469 DOI: 10.1016/j.ijmm.2018.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
15 Janapatla RP, Chen CL, Hsu MH, Liao WT, Chiu CH. Immunization with pneumococcal neuraminidases NanA, NanB and NanC to generate neutralizing antibodies and to increase survival in mice. J Med Microbiol 2018;67:709-23. [PMID: 29557769 DOI: 10.1099/jmm.0.000724] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
16 Gómez Delgado I, Corvillo F, Nozal P, Arjona E, Madrid Á, Melgosa M, Bravo J, Szilágyi Á, Csuka D, Veszeli N, Prohászka Z, Sánchez-Corral P. Complement Genetic Variants and FH Desialylation in S. pneumoniae-Haemolytic Uraemic Syndrome. Front Immunol 2021;12:641656. [PMID: 33777036 DOI: 10.3389/fimmu.2021.641656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Petruzziello-Pellegrini TN, Marsden PA. Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens 2012;21:433-40. [PMID: 22660553 DOI: 10.1097/MNH.0b013e328354a62e] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]